Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic letter to FDA objects to warning letter's implication of corporate-wide distribution problems.

This article was originally published in The Gray Sheet

Executive Summary

MEDTRONIC CHALLENGES FDA IMPLICATION OF CORPORATE-WIDE DISTRIBUTION PROBLEMS in a March 24 letter to the agency. The firm issued the correspondence in response to a March 10 FDA warning letter that cited Medtronic's Minneapolis-based Neurological Division for good manufacturing practice violations in the assembly and shipment of the Synchromed implantable drug infusion pump. The company says FDA's warning letter wrongfully implies that there are systematic defects in Medtronic's shipping processes.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007829

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel